MicroPort CardioFlow Medtech Corporation filed its monthly return to Hong Kong Exchanges and Clearing on 7 May 2026, confirming that authorised and issued share capital remained unchanged throughout April 2026.

Authorised Capital • Authorised share capital stayed at 2.00 billion ordinary shares with a par value of USD 0.000025, representing total authorised capital of USD 50,000.

Issued Shares and Treasury Position • Issued shares (excluding treasury shares) held steady at 1.27 billion. • The company held no treasury shares, and there were no repurchases or cancellations during the month. • Consequently, total issued share capital also closed the month at 1.27 billion shares.

Public Float • Management confirmed compliance with the Main Board’s minimum public-float threshold of 25 percent as of 30 April 2026.

Share Option Activity • Option Scheme (approved 13 Mar 2020): 10.74 million options outstanding at March-end declined by 0.14 million due to cancellations, leaving 10.60 million outstanding. • Share Scheme (approved 27 Jun 2023): 4.85 million options outstanding fell by 0.02 million, finishing the month at 4.83 million. • No options were exercised; therefore, the issued-share count and the company’s cash position were unaffected. • Shares still available for potential future issuance comprise 9.73 million under the option scheme and 1.56 million under the share scheme, with an additional 41.17 million shares eligible for grant under the 2023 scheme.

Fund-Raising Impact • The company raised no proceeds from option exercises in April.

With no changes in share count, treasury position or fund-raising activity, MicroPort CardioFlow’s equity structure remains consistent heading into May 2026.